Proviral insertion of Moloney virus (PIM) 1, 2, and 3 kinases are serine/threonine kinases that normally function in survival and proliferation of hematopoietic cells. As high expression of PIM1, 2, and 3 is frequently observed in many human malignancies, including multiple myeloma, non-Hodgkins lymphoma, and myeloid leukemias, there is interest in determining whether selective PIM inhibition can improve outcomes of these human cancers. Herein, we describe our efforts toward this goal. The structure guided optimization of a singleton high throughput screening hit in which the potency against all three PIM isoforms was increased >10,000-fold to yield compounds with pan PIM K i s < 10 pM, nanomolar cellular potency, and in vivo activity in an acute myeloid leukemia Pimdependent tumor model is described. KEYWORDS: Proviral insetion site in Moloney murine leukemia virus kinases inhibitors, Pim1 kinase inhibitor, Pim2 kinase inhibitor, Pim3 kinase inhibitor, pan-Pim kinase inhibitors Figure 1. Pim clinical compounds and starting point 1a. Letter pubs.acs.org/acsmedchemlett
P roviral insertion site of Moloney murine leukemia virus kinases, or PIM 1, 2, and 3 kinases are constitutively active serine/threonine kinases that normally function in the survival, proliferation, and differentiation of hematopoietic cells in response to growth factors and cytokines. 1,2 PIM's play redundant roles in oncogenesis and, therefore, suggest that a pan-PIM kinase inhibitor may be clinically useful. 3 In human disease, high expression and/or dysfunction of the three PIMs has been implicated in the progression of hematopoetic and solid tumor cancers. 1, 2 In addition to cancer, PIM kinases have been reported to play a role in several autoimmune diseases. 4 Not surprisingly, PIM kinases have emerged as attractive therapeutic targets and have elicited several groups to investigate and report novel inhibitors of PIM 5−10 including the clinical compounds SGI-1776 6 and AZD1208, 7 Figure 1 . Pim kinases share a high level of sequence homology within the family (>61%) and all share the unique feature of being the only kinases with a proline in the hinge, 11 which results in only one hydrogen bond interaction with ATP. As the ATP K m for PIM2 is 10−100× lower than that for PIM1 and PIM3, cell active pan PIM inhibitors have been more challenging to identify than PIM 1/3 inhibitors. Herein, we describe potent and selective cell active inhibitors of all three PIM kinases. A representative of this compound series, 5c, has suitable PK properties and was recently used to establish a PK/PD efficacy relationship in a PIM2 driven multiple myeloma xenograft model. 12 Here we also demonstrate efficacy in the AML EOL-1 xenograft model. The starting point for our discovery efforts was the singleton high throughput screening hit 1a. While of modest pan PIM potency, we followed up on it due to its low molecular weight (344), good PIM1 ligand efficiency (LE = 0.41, FQ = 1.01) and a presumed nonplanar ground state conformation for the ortho-substituted acylaniline moiety, which we reasoned might ultimately be beneficial with respect to physicochemical properties.
Prior to starting any synthetic chemistry efforts, a cocrystal structure of compound 1a in PIM1 was obtained, Figure 2 . 13 We were intrigued by several aspects of the binding interactions (or lack thereof), which suggested multiple avenues to increase potency and, importantly, not necessarily increase the size or lipophilicity. First, there was no H bonding interaction to the hinge (or any other part of the protein). Second, the phenyl group was positioned in proximity to the catalytic Lys67. Third, the piperidine was in a chair conformation with well-defined vectors to access potential hydrogen bonding interactions in the acidic patch below and hydrophobic interactions to the glycine rich loop above. Additionally, the NH-acetyl substituent extended toward the hydrophobic lower hinge, making no hydrogen bonds. Furthermore, the central amide in the molecule made no hydrogen bonds as well, appearing to serve only as a rigid linker connecting the phenyl and thiazole rings.
Hit optimization efforts were initiated by variation of the piperidine (A ring), phenyl (B ring), and N−Ac thiazole (C ring) components of compound 1a. PIM1−3 kinase activity was assessed initially in a Kinase-Glo assay, with [ATP] at or below ATP K m for each isoform. As compound potency increased, vide infra, the assay format was changed to a high [ATP] Alphascreen format to extend the assay sensitivity. Compound enzymatic data is presented as K i s to allow comparison of activity of compounds run in the two assay formats. Removal of the N−Ac from the thiazole 1a starting point yielded 1b with >10× reduced potency, Table 1 . From this weakly potent compound lacking any extensions to the lower hinge, modifications in the C ring with heterocycles were surveyed. Of note, aminopyrazine 1c increased potency relative to 1b as well as demonstrating measurable PIM2 potency with no extenstion to the lower hinge and with a half unit reduction in cLogP. Modification of the phenyl B ring in 1a targeted potential hydrogen bonding interactions with catalytic Lys67. Multipe heterocycles and amino or hydroxy substituted heterocycles gave marginal improvement in potency. However, it was noted that B ring pyridine 2b maintained the potency of the lead 1a, while having a 0.5 unit reduction in cLogP. Combination of the aminopyrazine C ring and pyridine B ring led to compound 3a with a clogP of 1.9, a 3× improved potency against PIM1 and 3 and now measurable PIM2 potency (≥ 10× improvement). From 3a, variation of the piperidine A ring with various amine and amide substituted hetereocycles, which could potentially interact with the protein side chain carboxylates and backbone amides in the ribose patch (Asp128 and Glu171), was targeted. While most modifications offered little if any potency advantage over 3a, the 3-S amino piperidine compound 3f stood out with increased potency while further lowering the cLogP to 0.6. From only limited kinase profiling of 3f it was apparent that the aminopyrazine was fairly promiscuos with its donor and acceptor hinge motif 14 as relative to PIM inhibition several non-PIM kinases were inhibited with equivalent or greater potency. 15 At this time, the unique nature of the PIM hinge was exploited by switching to the donor only C ring aminopyridine 3g, which maintained comparable PIM potencies relative to 3f, but with a >100 potency reduction in the non-PIM kinases tested. 16 From compound 3g (cLogP = 1.3, cLogD 7.4 = −0.7), the lower hinge was explored with an eye toward improving potency even if it came at the expense of increased lipophilicity as an ultimate logD7.4 of 1−3 was targeted. The chemistry was amenable to extensive variation (via a C ring 6-bromo-3aminopyridine) with oxygen, nitrogen, and carbon linkages explored, Table 2 . Potency gains were realized as many compounds reached the limits of detection in the low [ATP] assay conditions. Ultimately, the 2,6 difluorophenyl proved highly potent with compound 4j exhibiting picomolar 17 pan PIM potencies while retaining a reasonable lipophilicity (cLogP = 3.7, cLogD 7.4 = 1.5). Notably, the panPIM potency increase of 4j relative to 3g did not translate into a similar potency increase for the non-PIM kinases tested, as the selectivity window actually widened. 18 Further optimization of 4j focused on improving overall drug-like properties, Table 3 . Incorporation of a trans hydroxy on the piperidine, 5a, reduced the lipophilicity while maintaining picomolar pan Pim potency. Attempts to increase potency further with minimal increase in lipophilicity included evaluation of a 5-fluoro substituent on the carboxypyridyl ring as well as targeting a hydrophobic dimple in the glycine loop with additional substituents on the piperidine ring. Incorporation of both of these modifications in the methyl-, hydroxy-, and amino-substitued piperidine 5b did indeed increase the panPim potency. With the hydroxy addition to the aminopiperidine, it was noted that the PSA, 130, of 5b as well as number of hydrogen bond donors, six, was increasing. A reduction in both properties was then pursued for potential improvement of overall drug like properties. As the original lead lacked any hinge interaction with PIM kinases, we proceeded to ask the question of whether from these optimized ligands the hinge amino donor interaction could be removed without compromising potency. The hinge donor interaction could indeed be removed without a dramatic loss in potency, as compound 5c maintained picomolar enzymatic activity and low nanomolar cellular activity, vide infra. When compared alongside the clinical compounds SGI-1776 and AZD1208, 5c is more potent in enzymatic and cellular, vide infra, assays. As may be expected with no potential hinge interacting moiety, kinase profiling of 5c using the KINOME scan binding displacement assay indicated high kinase selectivity [S(35) = 0.026 at 1 μM, 442 kinases). With a measured logD 7.4 of 2.2 and K i s of 1−2 picomolar for PIMs 1−3, the LLE of 5c is quite high (8.4 with respect to cLogP and 9.2 with respect to measured logD 7.4 ).
The crystal structure of 5c in PIM-1 was obtained, Figure  3 . 19 The overall binding mode is the same as the original lead 1a with the central amide making no hydrogen bonds and displaying the two sides of the molecule toward the hinge/ lower hinge and catalytic Lys region/ribose patch. The amino group on the piperidine ring makes two hydrogen bonds to the Asp128 side chain carboxylate and the Glu171 backbone carbonyl in the ribose patch. Additionally, the methyl group fills a hydrophobic dimple in the glycine rich loop above. The B ring pyridine nitrogen makes a hydrogen bond with the catalytic Lys 67. The C ring fluoropyridine fills the Pro123 hinge region with no hydrogen bond interactions and the difluorophenyl ring extends into the lower hinge region. The picomolar enzymatic PIM activity of 5a−5c translates to nanomolar cellular activity in mechanism target modulation and antiproliferative cell assays for cell lines dependent on PIM1, 2, or 3. For example, in the multiple myeloma derived KMS-11 luc cell line with high expression levels of PIM2, compound 5c inhibits phosphorylation of pBAD Ser112 (a direct substrate) at 10 nM, inhibits phosphorylation of pS6RP Ser240/4 (a downstream substrate) at 38 nM and inhibits cell proliferation at 17 nM. 12 The large upward potency shift in going from the enzyme to cells was consistent with the low ATP K m for PIM2. 20 In comparison, SGI1776 and AZD1208 inhibit cell proliferation in the KMS-11luc cell line at 4500 and 680 nM, respectively. In the acute myeloid leukemia derived EOL-1 cell line, 21 compound 5c inhibits cell proliferation at <40 nM.
As a highly kinase selective and cell active pan-PIM inhibitor, compound 5c was next assessed for it is potential to serve as a tool to study the effect of PIM kinase inhibition in vivo. The close focus on controling lipophilicity during potency optimization proved beneficial as 5c did indeed possess suitable in vivo properties. Upon dosing 5 mg/kg IV and 10 mg/kg PO of 5c to mice, a CL of 25 mL/min/kg, a bioavailabity of 55% and a Vss of 4 L/kg were determined. Upon dosing 10 mg/kg IV and 20 mg/kg PO of 5c to rats, a CL of 13 mL/min/kg, a bioavailabity of 44%, and a Vss of 3.4 L/kg were determined. The favorable physical properties of 5c were further reflected in the ability to conduct the in vivo studies using acetate buffer formulations. At higher oral doses in both species (up to 100 mg/kg) the plasma exposure increased in a roughly proportional manner relative to the screening PK studies, vide infra. As such, free plasma levels of 5c 22 in excess of the cellular target modulation and antiproliferative EC 50 s can be achieved and maintained in rodents.
The target modulation and antiproliferative activity of 5c in a multiple myeloma (KMS-11.luc) tumor xenograph model has been recently reported. 12 Continual modulation of target, as judged by pS6RP inhibition, was associated with maximal efficacy. In addition to antitumor activity in the multiple myeloma model, here we demonstrate efficacy in the EOL-1 acute myeloid leukemia xenograph model. Administration of 5c at 30 and 100 mg/kg daily yields significant dose-dependent reduction in tumor growth, Figure 4 . Both doses tested were well tolerated, as judged by minimal body weight loss (within a margin of 5% of initial weight) observed for both groups.
In summary, the structure guided optimization of singleton screening hit 1a in which the potency against all three PIM isoforms was increased >10,000-fold, with no increase in lipophilicity, to yield compound 5c that exhibits single digit picomolar pan PIM potency, high kinase selectivity, and in vivo properties suitable to achieve efficacy in an acute myeloid leukemia PIM-dependent tumor model has been described. During the optimization, a focus was initially placed on increasing potency while simultaneously reducing the liphophilicity, as enthalpic contributors to potency were identified. From this lowered clogP space, a hydrophobic interaction was optimized ultimately yielding compound 5c. Our continued efforts toward bringing forward selective and potent pan PIM kinase inhibitors to benefit cancer patients will be reported in due course. 
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